Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ

Authors: Ameriks, Michael K.; Venable, Jennifer D.

Source: Current Topics in Medicinal Chemistry, Volume 9, Number 8, May 2009 , pp. 738-753(16)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.

Keywords: PI3K; inflammation; allergy; asthma; rheumatoid arthritis; COPD

Document Type: Research article

DOI: http://dx.doi.org/10.2174/156802609789044434

Affiliations: 1: Johnson & Johnson Pharmaceutical Research & Development L.L.C. San Diego, CA 92121, USA.

Publication date: 2009-05-01